Litigation In Brief
This article was originally published in The Gray Sheet
Executive Summary
Medtronic v. NuVasive, round one
You may also be interested in...
Court Wants To Reassess Damages In NuVasive/Medtronic Patent Fight
In a long-standing patent fight between NuVasive and Medtronic, an appeals court has ruled NuVasive was being penalized twice for lost profits based on damages awarded by a jury. The judges unanimously agreed to send the case back to a district court to reevaluate how much Medtronic should be paid.
Syneron Expects Candela Acquisition To Expand Aesthetics Marketing Reach
Syneron Medical aims to extend its global sales reach and obtain new dermatologist and cosmetic surgeon customers through its $65 million purchase of fellow aesthetic device maker Candela
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.